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ABSTRACT
While both human sphingosine kinases (SK1 and SK2) catalyze the generation 
of the pleiotropic signaling lipid sphingosine 1-phosphate, these enzymes appear 
to be functionally distinct. SK1 has well described roles in promoting cell survival, 
proliferation and neoplastic transformation. The roles of SK2, and its contribution 
to cancer, however, are much less clear. Some studies have suggested an anti-
proliferative/pro-apoptotic function for SK2, while others indicate it has a pro-
survival role and its inhibition can have anti-cancer effects. Our analysis of gene 
expression data revealed that SK2 is upregulated in many human cancers, but only 
to a small extent (up to 2.5-fold over normal tissue). Based on these findings, we 
examined the effect of different levels of cellular SK2 and showed that high-level 
overexpression reduced cell proliferation and survival, and increased cellular ceramide 
levels. In contrast, however, low-level SK2 overexpression promoted cell survival and 
proliferation, and induced neoplastic transformation in vivo. These findings coincided 
with decreased nuclear localization and increased plasma membrane localization of 
SK2, as well as increases in extracellular S1P formation. Hence, we have shown for 
the first time that SK2 can have a direct role in promoting oncogenesis, supporting 
the use of SK2-specific inhibitors as anti-cancer agents.
INTRODUCTION
The sphingosine kinases (SKs) catalyze the 
conversion of sphingosine to sphingosine 1-phosphate 
(S1P). Given that sphingosine and its precursor, ceramide, 
are pro-apoptotic molecules, and S1P mediates cell 
survival and proliferation [1, 2], the SKs are considered 
critical regulators of the balance between cell death and 
cell survival, and represent promising targets for anti-
cancer therapies [3]. The two mammalian SKs, SK1 and 
SK2, share high sequence similarity and both possess 
constitutive catalytic activity, but generally show distinct 
subcellular localization [4].
The role of SK1 in cancer is well characterized 
and has been extensively reviewed [1, 2, 5], with high 
SK1 expression observed in many different cancers and 
often correlating with poorer patient survival [5]. SK1 
overexpression promotes neoplastic transformation and 
tumorigenesis [6], and notably, targeting SK1 has been 
shown to attenuate tumor growth in numerous animal 
models [3]. In contrast, the contribution of SK2 to cancer 
is unclear. Surprisingly, despite both enzymes catalyzing 
the same reaction, most studies examining SK2 function 
have found that it has an opposite role to SK1, and can 
promote cell cycle arrest and apoptosis [7-11]. Although 
most of these studies utilized high-level overexpression 
systems, functional analysis of endogenous SK2 has 
supported this role in promoting cell death [9, 11, 12]. 
Most notably, nuclear-localized SK2 has been shown 
to act as an epigenetic regulator, through S1P-mediated 
inhibition of histone deacetylase 1/2 (HDAC1/2) activity 
and increased transcription of p21 and c-fos [13].
                  Research Paper
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Despite this general notion that SK2 is pro-
apoptotic, a number of studies have emerged that 
demonstrate a role for SK2 in promoting cancer. 
Knockdown of SK2 expression has been shown to 
enhance apoptosis and chemosensitize many cancer cell 
types [14-17]. In fact, targeting SK2 in a range of cancer 
cell lines appears to have more of an anti-cancer effect 
than targeting SK1 [14, 18]. Strikingly, several in vivo 
studies have reported that targeting SK2 significantly 
attenuated tumor growth in a range of human xenograft 
models in mice [19-23]. Increased SK2 expression levels 
also correlate with disease progression in non-small cell 
lung cancer (NSCLC) [24] and multiple myeloma [25], 
and poorer survival in NSCLC patients [24]. Recent 
work also suggests that SK2 can play a role in increasing 
telomerase activity [26], promoting the upregulation of 
c-Myc via regulation of HDAC1/2 [20], and facilitating 
the activation of ezrin-radixin-moesin proteins to promote 
EGF-induced cancer cell invasion [27], all of which may 
contribute to cancer development and progression. 
Although there is an emerging body of evidence 
suggesting that SK2 can play a role in cancer development, 
this is complicated by the known role of SK2 in facilitating 
cell death, and that, unlike SK1, SK2 overexpression has 
never been shown to promote neoplastic transformation 
and tumorigenesis. Here, we demonstrate for the first 
time that low-level SK2 overexpression, similar to 
that observed in numerous cancers, can promote cell 
proliferation, survival and neoplastic transformation, and 
that these levels of SK2 overexpression alone can drive 
tumorigenesis in vivo. 
RESULTS
SK2 expression is elevated in a wide range of 
human cancers
Despite numerous studies examining the targeting of 
SK2 in cancer, broad analysis of SK2 expression in cancer 
has not been previously performed. Thus, we examined 
SK2 expression in a wide range of human cancers using 
the public gene expression datasets in the Oncomine 
database [28]. We found that SK2 is significantly elevated 
in studies from a broad range of human cancers, including 
bladder, melanoma, esophageal, breast, lymphoma and 
leukemia (Figure 1A and Supplementary Figure S1A). 
Figure 1: Low-level SK2 overexpression is observed in human cancers, and can promote cell survival and proliferation. 
A. Heat map showing human cancers where significant (p < 1x10-4) upregulation of SK2 mRNA levels have been observed in cancerous 
tissues compared with corresponding normal tissue. Data was extracted from the Oncomine database [28], where each row represents a 
cancer subtype from an individual dataset. Further detail is presented in Supplementary Figure S1A. B. SK1 and SK2-specific activity 
upon doxycycline (dox)-induced low- and high-level overexpression in HEK293 Flp-In T-Rex cells. Data shown are mean (± range) 
of duplicate data points from a representative experiment (of more than three independent experiments). C. Lysates from the HEK293 
Flp-In T-Rex cells with doxycycline-induced low- and high-level overexpression of FLAG-tagged SK1 or SK2, or empty vector, were 
subjected to immunoblot analyses with antibodies against FLAG and α-tubulin. Blots shown are representative of at least three independent 
experiments. D. Measurement of cell proliferation in HEK293 Flp-In T-Rex cells with doxycycline (dox)-induced low- and high-level 
overexpression of SK1 or SK2, or empty vector. Data shown are mean ± SEM, n = 3-4. Statistics were performed using an unpaired 
Student’s t-test (two-tailed); ***p < 0.001, ****p < 0.0001. E. Measurement of cell death in HEK293 Flp-In T-Rex cells with doxycycline 
(dox)-induced low- and high-level overexpression of SK1 or SK2, or empty vector. Data shown are mean ± SEM, n = 4-5. Statistics were 
performed using an unpaired Student’s t-test (two-tailed); **p < 0.01, ***p < 0.001.
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Interestingly, however, this cancer-associated elevation in 
SK2 was only modest, with up to 2.5-fold higher levels 
of SK2 compared with the corresponding normal tissues. 
Notably, both SK1 and SK2 were upregulated in three 
independent datasets for diffuse large B-cell lymphoma 
(Supplementary Figure S1B), but there was no apparent 
general correlation between SK2 and SK1 upregulation in 
the other tumors examined. Indeed, in most other tumor 
datasets where SK2 was upregulated, SK1 expression 
was either unaltered or significantly downregulated 
(Supplementary Figure S1B).
Low-level SK2 overexpression enhances cell 
survival and proliferation, whereas high-level 
overexpression promotes cell death
Many studies have demonstrated that high-level 
SK2 overexpression can promote cell cycle arrest and 
cell death [7-10]. However, based on the gene expression 
analysis showing only low levels of SK2 overexpression 
in human cancers, we reasoned that more informative 
functional analysis would be gained by overexpression 
Figure 2: Generation of NIH3T3 stable cell lines with varying levels of constitutive SK2 overexpression. A. The NIH3T3 
pooled stable cell line expressing SK2 and GFP, or GFP alone (empty vector), were sorted on four separate narrow gates of varying GFP 
intensity (colored boxes in top panel), to produce new stable lines depicted as ‘very low’, ‘low’, ‘mid’ and ‘high’. These new stable lines 
were then analyzed by flow cytometry to confirm that the desired narrow GFP-expression levels were obtained as expected. GFP-negative 
control cells are depicted by a dotted line. B. SK2-specific activity of NIH3T3 cell lines stably expressing ‘very low’ (5-fold), ‘low’ (10-
fold), ‘mid’ (20-fold) or ‘high’ (440-fold) levels of SK2 overexpression (above endogenous levels), or empty vector. Data are shown as 
mean (± range) of duplicate samples from a representative experiment, of at least three independent experiments. C. Lysates from the 
NIH3T3 vector or SK2 overexpressing cell lines were subjected to immunoblot analyses with antibodies against FLAG, GFP and α-tubulin. 
Blots shown are representative of at least three independent experiments.
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of SK2 at much lower levels. To investigate this, we 
utilized human embryonic kidney (HEK) 293 cells 
engineered to express FLAG-tagged SK2 or SK1 in a 
doxycycline-inducible, concentration-dependent manner. 
Using different doxycycline concentrations in the culture 
media, we could achieve low and high SK2 and SK1 
overexpression, as determined by specific-activity (Figure 
1B) and protein expression (Figure 1C). Importantly, 
endogenous SK2 and SK1 protein levels remained 
unaltered upon induction of SK1 and SK2 overexpression, 
respectively (Supplementary Figure S2A and S2B). We 
then used this system to assess the effect of varying levels 
of SK overexpression on cell proliferation and survival. In 
agreement with previous studies, overexpression of SK2 
at high levels (over 200-fold) in this system resulted in 
decreased cell proliferation and an increase in cell death 
(Figure 1D and 1E). Strikingly, however, when SK2 
was overexpressed to much lower levels (8-fold over 
endogenous), more comparable to that seen in the cancer 
expression analysis, this induced a marked increase in cell 
proliferation and a decrease in cell death (Figure 1D and 
1E). These contrasting findings clearly demonstrate that 
the cellular levels of SK2 influence its function. Notably, 
these findings were unique to SK2, with both low- and 
high-level overexpression of SK1 resulting in a consistent 
increase in cell survival and proliferation (Figure 1D and 
1E).
SK2 can elicit oncogenic signaling and promote 
neoplastic transformation in vitro
Next, we assessed if low-level overexpression 
of SK2 could also induce neoplastic transformation, as 
had been previously observed for SK1 [6]. In contrast to 
mouse cells, neoplastic transformation of human cells is 
well known to require multiple oncogenes [29], meaning 
their use in these type of studies is problematic. Thus, to 
Figure 3: SK2 overexpressed at low levels can elicit oncogenic signaling and drive neoplastic transformation in vitro. 
A. Lysates from the NIH3T3 vector or SK2-overexpressing cell lines were subjected to immunoblot analyses and probed with antibodies 
against phospho-AKT, total AKT, phospho-ERK1/2, total ERK1/2, FLAG, GFP, SK1 and α-tubulin. Vect = empty vector with ‘low’ level 
GFP expression, chosen as a representative control. Densitometry was performed to quantify phospho-AKT and phospho-ERK band 
intensities, and is presented as a ratio of total AKT and ERK levels, respectively, and is normalized to vector. Blots shown are representative 
of three independent experiments. B. Contact inhibition of the NIH3T3 vector or SK2-overexpressing cell lines was tested using focus 
formation assays. Images shown are representative of at least three independent experiments, each performed in duplicate, using at least 
three independently generated sets of stable lines. C. Number of foci per well from the experiment shown in Figure 3B were quantified and 
the mean number of foci for duplicate wells was graphed (± range).
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examine the oncogenic potential of SK2, we transfected 
NIH3T3 mouse fibroblasts with a vector encoding SK2 
as well as green fluorescent protein (GFP) via an internal 
ribosome entry site (IRES) such that GFP and SK2 
expression were linked. We then isolated a series of cell 
lines stably expressing different levels of SK2 through the 
sorting of cells for differential GFP expression (Figure 
2A). The resulting stable cell lines were then validated 
through the analysis of SK2-specific activity (Figure 
2B) and exogenous SK2 protein levels (Figure 2C), 
which revealed stable overexpression of SK2 at 5-fold, 
10-fold, 20-fold and 440-fold over endogenous levels, 
designated ‘very low’, ‘low’, ‘mid’ and ‘high’ level SK2 
overexpression, respectively. 
Biochemical analysis of these cell lines revealed 
that ‘low’ SK2 overexpression resulted in the activation 
of oncogenic signaling pathways, as demonstrated by an 
increase in phospho-AKT and phospho-ERK1/2 levels 
(Figure 3A). Conversely, the ‘mid’ and ‘high’-level SK2 
overexpression caused a downregulation of phospho-
ERK1/2 signaling (Figure 3A), in agreement with high-
level SK2 overexpression attenuating cell proliferation. 
Also consistent with the HEK293 Flp-In T-Rex 
overexpression system, endogenous SK1 protein levels 
were unchanged in the multiple SK2-overexpressing 
NIH3T3 cell lines, as compared to vector control cells 
(Figure 3A). These cells were then utilized in in vitro 
assays of neoplastic cell transformation. Notably, in focus 
formation assays, cell lines with ‘very low’, ‘low’ and 
‘mid’-level SK2 overexpression formed foci, whereas 
cells with ‘high’-level SK2 overexpression did not 
(Figure 3B and 3C). Similar results were also observed 
in colony formation assays (Supplementary Figure S3), 
demonstrating that low-level SK2 overexpression can 
promote anchorage-independent growth in soft agar. 
Together, these data demonstrate that low-level SK2 
overexpression can elicit oncogenic signaling and induce 
neoplastic transformation of cells.
Low-level SK2 overexpression can drive tumor 
formation in vivo
Given that SK2 could promote neoplastic growth in 
vitro, we next examined if this represented full neoplastic 
transformation through analyzing the ability of these 
cells to form tumors in vivo. Hence, the series of cell 
lines with differential levels of SK2 overexpression were 
subcutaneously engrafted into the flanks of NOD/SCID 
mice, and the development of tumors assessed. Consistent 
with the in vitro data, cells with either ‘very low’ or ‘low’ 
SK2 overexpression resulted in efficient tumor formation 
in mice (Figure 4A). In stark contrast, however, cells with 
either ‘mid’ or ‘high’ SK2 overexpression showed minimal 
tumor growth (Figure 4A). All tumors were vascularized, 
as determined by CD31 staining, and showed morphology 
characteristic of fibrosarcoma (Supplementary Figure 
S4A and S4B). Notably, the tumors that developed from 
the ‘very low’ SK2 cells were significantly larger than all 
other tumors formed (Figure 4B and 4C). Overall, these 
results demonstrate for the first time that through low-level 
overexpression, SK2 can drive tumorigenesis in vivo. 
Although the SK2-expressing cells engrafted into 
mice were fractionated based on their GFP (and therefore 
SK2) expression, these cells remained pools of clones. 
While this obviates potential defects associated with 
plasmid integration into the genomes of individual clones, 
it meant that the level of SK2 overexpression observed 
for each line was an average of all cells within that line. 
Thus, we examined the expression levels of SK2 within 
the resulting tumors. Notably, every tumor that developed 
from the ‘very low’, ‘low’ and ‘mid’ SK2 overexpressing 
cells all possessed very similar levels of SK2 protein 
(Figure 4D) and catalytic activity (Figure 4E). Indeed, by 
comparison to the parental fibroblast cells, it appears that 
tumor formation resulted preferentially from cells within 
the pools with less than 5-fold SK2 overexpression (Figure 
4E). This finding suggests that this level of SK2 represents 
the optimal level to promote oncogenic signaling and 
tumorigenesis, and is consistent with the low level of 
SK2 upregulation seen in many human cancers (Figure 
1A). These results perhaps explain why only one tumor 
formed from the ‘mid’ SK2-expressing cells, as within 
this pool of cells there would likely be fewer low SK2-
expressing clones compared with the ‘low’ and ‘very low’ 
groups. Unexpectedly, the ‘high’ SK2-overexpressing 
cells also resulted in one tumor forming. Further analyses, 
however, revealed that cells within this tumor were not 
actively proliferating, whereas cells within the tumors 
generated from ‘very low’ SK2-expressing cells were 
highly positive for the proliferation marker Ki-67 (Figure 
4F). Furthermore, the level of SK2 overexpression 
within the ‘high’ SK2 tumor was quite heterogeneous, 
with only small patches of cells with high levels of SK2 
protein (Figure 4G). In fact, the majority of the tumor was 
comprised of cells with low SK2 overexpression similar 
in level to that seen in the tumors arising from ‘very low’ 
SK2-expressing cells (Figure 4G). Therefore, again, it is 
possible that a small population of cells within the original 
‘high’ cell pool drifted to low-level SK2 overexpression 
and initiated tumor formation, thus supporting the growth 
of some of the high SK2-expressing cells. Indeed, our data 
demonstrating that low SK2 overexpression supported 
enhanced cell proliferation and survival, while high 
SK2 overexpression had the opposite effect suggests 
that the high SK2-expressing cells would have been 
under considerable selective pressure towards low SK2 
overexpression.
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Figure 4: Low-level SK2 overexpression can drive proliferation and tumorigenesis in vivo. NOD/SCID mice were injected 
with NIH3T3 cell lines stably overexpressing ‘very low’ (5-fold), ‘low’ (10-fold), ‘mid’ (20-fold) or ‘high’ (440-fold) levels of SK2 
(above endogenous levels). Empty vector cells with ‘low’ level GFP expression were chosen as a representative control (Vector). A. Table 
summarizing the number of mice with tumors per cell line, 18 days post-cell injection. B. Images of the excised tumors from each group 
of NIH3T3 stable SK2 cell lines. Dashed lines indicate where the same image has been spliced together to aid interpretation. C. Weights 
of the excised tumors from each group of NIH3T3 stable SK2 cell lines. Statistics denote a significant increase in the weights of SK2 ‘very 
low’ tumors compared to tumors from the SK2 ‘low’, ‘mid’ and ‘high’ groups (* p < 0.05; Student’s unpaired two-tailed t-test). D. Equal 
amounts of total protein from the tumor tissue lysates were subjected to immunoblot analyses with antibodies against FLAG, α-tubulin 
and GFP. Each lane represents a different tumor sample. Dashed lines indicate where lanes from the same immunoblots have been spliced 
together to aid interpretation. E. SK2-specific activity from the tumor lysates was measured and graphed as mean (± range) of duplicate 
samples. These data were plotted alongside data of SK2 activity from the engrafted cell lines, which was transformed from Figure 2B 
as specific-activity (pmol S1P/min/mg protein) for the purposes of comparison. F. Dual immunofluorescence staining of overexpressed 
FLAG-tagged SK2 (red) and the proliferation marker Ki-67 (green) on the SK2 tumors. Tumor sections were counterstained with DAPI to 
indicate nuclei (blue). At least five random fields of view were imaged per tumor and representative images are shown. Scale bar = 50 µm. 
G. Levels of SK2 overexpression are heterogeneous in the SK2 ‘high’ tumor. Staining of overexpressed FLAG-tagged SK2 was visualized 
by immunohistological analyses. Multiple images were taken for each tumor and a representative field of view is shown. Arrow denotes a 
representative area of heterogeneous, intense FLAG (SK2) staining in the SK2 ‘high’ tumor. Scale bar = 100 µm.
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Differential levels of SK2 overexpression alter 
its subcellular localization and sphingolipid 
metabolism
It is well established that the subcellular localization 
of the SKs, and hence the compartmentalization of S1P 
within the cell, plays an important role in the function of 
these enzymes [30]. The oncogenic role of SK1 requires 
its translocation to the plasma membrane, a location that 
results in increased extracellular S1P production [31]. 
Furthermore, the localization of SK2 to the nucleus, 
endoplasmic reticulum (ER) or mitochondria appears to 
promote its anti-proliferative, pro-apoptotic functions [7, 
8, 11, 13]. Thus, we examined the localization of SK2 
when overexpressed at low and high levels. In the ‘high’ 
SK2-expressing cells, SK2 was strongly nuclear-localized 
(Figure 5A and 5B), in agreement with previous reports 
for this cell type [7]. In the ‘low’ SK2-expressing cells, 
however, SK2 was mostly cytoplasmic, and showed a 
significant increase in its plasma membrane localization 
(Figure 5A and 5C). Furthermore, the formation of 
extracellular S1P was significantly higher from cells 
with ‘low’-level SK2 overexpression compared to vector 
control cells (Figure 6A), consistent with our observations 
of increased SK2 at the plasma membrane in these cells. 
Interestingly, ‘high’-level SK2 overexpression resulted in 
a further increase in extracellular S1P formation (Figure 
6A), but this was only a modest doubling compared with 
the ‘low’ SK2 cells, despite these cells having greater than 
400-fold more SK2 activity.
Sphingolipid analysis revealed, somewhat 
surprisingly, that ‘low’-level SK2 overexpression had 
very little effect on the intracellular levels of S1P, 
ceramides, dihydroceramides, sphingomyelins or 
dihydrosphingomyelins (Figure 6B-6E), with the only 
change noted being a small increase in sphingosine. 
In contrast, ‘high’-level SK2 overexpression resulted 
in a significant increase in a range of ceramide species, 
sphingomyelins and dihydrosphingomyelins, as well 
as sphingosine (Figure 6B, 6D and 6E), in line with a 
previous report demonstrating that overexpressed SK2 
partially localized to the ER, and S1P produced here 
could feed into an ER/golgi-associated ‘salvage pathway’ 
to generate pro-apoptotic sphingosine and ceramide, as 
well as sphingomyelin [8]. The increase in ceramides 
and sphingosine are likely to contribute, at least in part, 
to the anti-proliferative and pro-cell death role of SK2 
in these ‘high’ overexpression cells, with the increase in 
extracellular S1P formation that was observed in these 
cells (Figure 6A) possibly insufficient to override these 
effects.
Figure 5: Varying levels of SK2 overexpression affect its subcellular localization. A. The subcellular localization of FLAG-
tagged SK2 (red) in the NIH3T3 stable ‘low’ and ‘high’ SK2-overexpressing cells was examined by immunofluorescence staining, using 
FLAG antibody. Nuclei were stained with DAPI (blue) and cell membranes were stained with antibodies against γ-catenin (green). Images 
are representative of cells observed from three independent experiments. Arrows denote representative plasma membrane localization of 
‘low’ SK2. Scale bar = 10 µm. B.-C. Cells from A. were visualized by confocal microscopy and scored based on the presence or absence 
of either B. distinct nuclear FLAG-tagged SK2 staining or C. plasma membrane-localized FLAG-tagged SK2 staining. A minimum of 
200 cells were scored per well, and data were graphed as mean (± SD) of triplicate wells from a single experiment, representative of three 
independent experiments (** p < 0.01; Student’s unpaired two-tailed t-test).
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DISCUSSION
Despite the conflicting data in the literature, our 
findings demonstrate that, like SK1, SK2 can have 
a physiological role in promoting cell survival and 
proliferation, potentially through plasma membrane 
localization. This is perhaps not surprising, as the 
individual genetic deletion of either SK1 or SK2 in mice 
does not result in any gross phenotypic abnormalities [32, 
33], whereas the double knock-out mice die in utero [34], 
suggestive of at least some functional redundancy between 
the two proteins. Like SK1, there are no mutations in 
SK2 linked to cancer, however it has been suggested that 
cancer cells can display a ‘non-oncogene addiction’ for 
SK1 [2, 35]. Given that we have now shown that SK2 can 
promote neoplastic transformation and tumorigenesis, and 
is upregulated in many human cancers, coupled with the 
anti-cancer efficacy of SK2-selective inhibitors leads us 
to postulate that a non-oncogene addiction may apply for 
both SKs in cancer. Indeed, targeting both SK isoforms 
may be the best strategy to overcome tissue and cell type-
specific differences in the roles of the SKs in different 
cancers, and in agreement, dual SK1/SK2 inhibitors show 
significant decreases in tumor burden in vivo [36, 37].
One of the most intriguing findings of our study 
is the observation that SK2 function can dramatically 
switch, depending on its expression level, from being 
pro-survival and pro-proliferative to pro-cell death and 
anti-proliferative. While it could be argued that high-level 
overexpression is non-physiological, and may generate 
Figure 6: Sphingolipid metabolism is altered when SK2 is overexpressed at varying levels. A. Rate of extracellular S1P 
formation was determined from intact vector control ‘low’, SK2 ‘low’ and SK2 ‘high’ NIH3T3 stable cell lines. Analyses were performed 
in triplicate and data are graphed as mean (± SD). Statistics denote significant increases in extracellular S1P compared to vector control 
cells (* p < 0.05, ** p < 0.01; Student’s unpaired two-tailed t-test). B.-E. Intracellular sphingolipid species were analyzed by LC-MS using 
NIH3T3 vector control ‘low’, SK2 ‘low’ and SK2 ‘high’ stable cell lines. Data are graphed as mean (± SD) of quadruplicate samples for 
B. individual ceramide species, sphingosine (Sph) and sphingosine 1-phosphate (S1P), C. individual dihydroceramide species, D. total 
sphingomyelin levels, and E. total dihydrosphingomyelin levels. Statistics denote significant increases in lipids compared to vector control 
cells (* p < 0.05, ** p < 0.01, *** p < 0.001; Student’s unpaired two-tailed t-test).
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artefacts, it is notable that previous studies have shown 
that SK2 can have physiological roles in promoting cell 
cycle arrest and apoptosis when localized to organelles 
such as the nucleus and mitochondria [11, 13]. Clearly, 
under normal conditions these pro-death roles are likely 
kept under tight regulation, so it remains possible that 
high-level overexpression circumvents these regulatory 
mechanisms. This high-level overexpression of SK2, for 
example, may lead to altered protein-protein interactions 
or post-translational modifications, altering the subcellular 
localization of SK2, from the plasma membrane to cellular 
organelles such as the nucleus, in favor of promoting cell 
death. Indeed, it has been previously reported that when 
transiently overexpressed, SK2 could interact with and 
sequester the pro-survival Bcl-xL protein [10], suggesting 
a possible mechanism for the pro-apoptotic phenotype 
we observed with high-level SK2 overexpression. 
However, despite multiple attempts, we were unable 
to detect an interaction between Bcl-xL and SK2 in our 
system, suggesting that this proposed interaction was 
unlikely to mediate the observed phenotype. Intriguingly, 
there appears to be a window whereby low-level 
SK2 upregulation confers a survival and proliferative 
advantage to the cell without inducing these pro-apoptotic 
functions. Whether a different subset of post-translational 
modifications and/or protein-protein interactions drive 
the differences in subcellular localization and function 
observed with low versus high SK2 overexpression will 
require further interrogation. 
To add further complexity, other studies have 
demonstrated that nuclear SK2 can contribute to cancer 
progression through the stabilization of telomerase 
and promotion of c-Myc expression [20, 26]. In the 
present study, SK2 was observed in the nucleus when 
overexpressed at high levels, and yet here it had an 
opposite, anti-proliferative role, which is also well 
documented [7, 13]. It is unclear how SK2 can have such 
vastly different functions within the same organelle, but it 
suggests that there must be additional factors regulating 
these processes. Indeed, the regulatory mechanisms 
controlling this enzyme remain an important, but currently 
largely unanswered question [4]. Notably, SK1 remains 
pro-survival and pro-proliferative even at high-level 
overexpression, likely due to its different subcellular 
localization to SK2 and consequent contribution to 
different sphingolipid pools within the cell. In line with 
this, previous studies have shown that artificially targeting 
SK1 to the ER can render it pro-apoptotic, like SK2 [8].
Interestingly, while cells with 20-fold (‘mid’) 
SK2 overexpression were able to form foci in vitro, they 
had decreased levels of phospho-ERK1/2 and did not 
efficiently form tumors in vivo. This may indicate that this 
level of SK2 overexpression is at the upper limit of the 
‘window’ whereby SK2 switches from being tumourigenic 
to having predominantly anti-proliferative functions. 
Conversely, 5-fold (‘very low’) SK2 overexpression 
resulted in no appreciable changes in phospho-ERK1/2 
or phospho-AKT levels, and yet these cells developed 
the largest tumors in vivo. It is therefore possible that 
S1P-mediated angiogenesis and tumor vascularization 
played more of an important role in the development of 
these tumors, given that low-level overexpression of SK2 
resulted in plasma membrane localization and increased 
formation of extracellular S1P, which is a key regulator 
of angiogenesis [38]. These observed differences also 
highlight the importance of employing in vivo models for 
assessment of full neoplastic transformation. Furthermore, 
it was surprising that ‘high’-level SK2 overexpression 
resulted in a doubling in extracellular S1P production as 
compared to the ‘low’-SK2 overexpressing cells, despite 
‘high’ SK2 overexpression resulting in decreased survival 
and proliferative signaling, and increases in pro-apoptotic 
sphingolipid species. Notably, Weigert et al. previously 
reported that transient overexpression of SK2 resulted 
in a substantial increase in S1P released from apoptotic 
cells as a result of SK2 being cleaved by caspase-1 and 
secreted from the cell [39]. This may, in part, explain our 
observed increase in extracellular S1P in the SK2 ‘high’ 
cells, which was clearly not able to facilitate any overall 
pro-survival or proliferative stimulus in these cells. It 
should be noted that Liang et al. found a significant 
increase in colitis-associated tumor development in SK2 
knockout mice, when compared to wildtype mice [40], 
suggesting that SK2 may function as a tumor suppressor 
in this model. However, these findings are likely to be 
an indirect effect as it was also shown in the study that 
the global genetic loss of SK2 caused an upregulation of 
both S1P receptor 1 and SK1 levels in the colon, with a 
concomitant increase in circulating and colonic S1P [40]. 
SK1 has been previously shown to contribute to colon 
carcinogenesis [41] and indeed, the increase in severity of 
colitis in the SK2 knockout mice was ablated by the SK1-
specific inhibitor SK1-I [40]. Furthermore, the proposed 
tumor-suppressive role of SK2 in negatively regulating 
pro-tumorigenic SK1 levels is not recapitulated with SK2-
selective inhibitors, which show efficacy in decreasing 
tumor burden in murine xenograft models [20-23].
Evidently the true functions of SK2 are complex 
and are also likely to be tissue- and cell type-specific. 
However, from our findings it is clear that SK2 represents 
an important target in cancer and future work to better 
understand how SK2 is regulated will be important for the 





The following primary antibodies were utilized: 
mouse monoclonal anti-FLAG (Clone M2 #F3165, 
Sigma-Aldrich), rabbit polyclonal anti-FLAG (#2368, 
Cell Signaling Technology), rabbit monoclonal anti-
FLAG (#14793, Cell Signaling Technology), mouse anti-
α-tubulin (#ab7291, Abcam, Cambridge, MA, USA), goat 
anti-GFP (#600-101-215, Rockland Immunochemicals, 
Limerick, PA, USA), rabbit anti-SK1 (#SP1621, ECM 
Biosciences, Versailles, KY, USA), rabbit anti-SK2 
(#17096-1-AP, Proteintech, Rosemont, IL, USA), rabbit 
anti-phospho-p44/42 MAPK (ERK1/2) Thr202/Tyr204 
(#9101, Cell Signaling Technology), rabbit anti-p44/42 
MAPK (ERK1/2) (#9102, Cell Signaling Technology), 
rabbit anti-phospho-AKT Ser473 (#9271, Cell Signaling 
Technology), rabbit anti-AKT (#9272, Cell Signaling 
Technology), mouse anti-Ki-67 (#VP-K452, Vector Labs, 
Burlingame, CA, USA), mouse anti-γ-Catenin (#610253, 
BD Biosciences) and goat anti-PECAM-1 (CD31; #SC-
1506, Santa Cruz Biotechnology, Dallas, TX, USA).
Generation of cell lines
HEK293 Flp-In T-Rex cells (Invitrogen, Life 
Technologies) with doxycycline-inducible FLAG-tagged 
SK1 or SK2 expression, or empty vector, were generated 
as previously described [42]. 
To generate NIH3T3 cells with varying levels 
of constitutive SK2 overexpression, we obtained 
a pCX-EGFP construct [43] that we initially 
modified by replacing the EGFP with a polylinker 
following digestion with EcoRI and ligation of 




to produce pCX4. pCX4-IRES EGFP was then generated 
by subcloning the IRES EGFP cassette from pcDNA3-
IRES EGFP [44] with EcoRI and NotI. pCX4-SK2(FLAG) 
IRES EGFP was then made by cloning in FLAG-tagged 
human SK2a [45] following digestion with EcoRI. 
NIH3T3 mouse fibroblasts (ATCC CRL-1658) were 
transfected with pCX4-SK2(FLAG) IRES EGFP, or empty 
vector, using Lipofectamine™ 2000 (Invitrogen) as per the 
manufacturer’s protocol. 48 h after transfection, the cells 
were sorted for GFP-positive cells using a MoFlo Astrios 
cell sorter (Beckman Coulter). A stable GFP-positive cell 
population was obtained by sorting for GFP another two 
times. The stable GFP-positive pooled line was then sorted 
on four separate narrow gates of varying GFP intensity, 
to produce new stable lines depicted as ‘very low’, 
‘low’, ‘mid’ and ‘high’. These new stable lines were then 
analyzed by flow cytometry to confirm that the desired 
narrow GFP-expression levels were obtained as expected.
Cell culture
HEK293 Flp-In T-Rex cells were cultured in 
Dulbecco’s modified Eagle’s medium (Gibco, Invitrogen), 
containing 10% fetal bovine serum (Bovagen), 1 mM 
HEPES, penicillin (1.2 mg/ml) and streptomycin (1.6 
mg/ml). NIH3T3 mouse fibroblasts were cultured in 
Dulbecco’s modified Eagle’s medium (Gibco, Invitrogen), 
containing 10% donor bovine serum with iron (DBS; 
Gibco, Invitrogen), 1 mM HEPES, penicillin (1.2 mg/ml) 
and streptomycin (1.6 mg/ml). All cells were grown at 
37°C, 5% CO2 in a humidified incubator.
For doxycycline-induced low- and high-level 
overexpression of FLAG-tagged SK1 and SK2, HEK293 
Flp-In T-Rex cells were seeded, and 24 h later media was 
removed and replaced with serum-free media containing 
0.1% bovine serum albumin (BSA; Sigma Aldrich) with 
either vehicle (methanol, 0.001% v/v final), 0.5 ng/ml 
or 100 ng/ml doxycycline (Sigma Aldrich). After 24 h 
induction, cells were harvested and lysates prepared. Cell 
proliferation and cell death were determined as previously 
described [36].
Immunoblot analysis
Cells were harvested by scraping into cold phosphate 
buffered saline (PBS), and cell pellets were resuspended 
in extraction buffer (50 mM Tris-HCl buffer (pH 7.4) 
containing 150 mM NaCl, 10% glycerol, 1 mM EDTA, 
0.05% Triton X-100, 2 mM Na3VO4, 10 mM NaF, 10 mM 
β-glycerophosphate, 1 mM dithiothreitol and protease 
inhibitor cocktail (Roche)). Cells were lysed by sonication, 
and total protein concentration was determined by a 
Bradford protein assay (Bio-Rad Laboratories, Hercules, 
CA, USA). Lysates of equal protein were separated by 
SDS-PAGE on a Criterion™ XT Bis-Tris 4-12% gradient 
gel (Bio-Rad Laboratories) under reducing conditions. 
Proteins were transferred to nitrocellulose membrane 
(Pall Life Sciences, Pensacola, FL, USA). Membranes 
were blocked using Odyssey® Blocking Buffer (LI-COR, 
Lincoln, NE, USA), and subjected to immunoblotting 
with various primary antibodies. Proteins were visualized 
using IRDye® secondary antibodies and the Odyssey® 
CLx infrared imaging system (LI-COR). Densitometry 




Focus formation assays were performed as 
described previously [6]. Briefly, cells were cultured to 
form monolayers in 6-well plates in DMEM with 1% DBS 
(Gibco, Life Technologies), and media was replenished 
every 2-3 days for a total of 3 weeks. Cells were then fixed 
in methanol, foci were stained with bromophenol blue, 
and images were taken using the Odyssey® CLx infrared 
imaging system (LI-COR).
Colony formation in soft agar
Colony formation assays in soft agar were performed 
as previously described [36]. After 14-21 days, colonies 
were quantified visually using light microscopy. Colonies 
were imaged using an Olympus MVX10 microscope.
In vivo tumor model
Experiments involving mice were conducted 
according to the guidelines from the Australian code 
of practice for the care and use of animals for scientific 
purposes 7th Edition, 2004, and with approval from the 
SA Pathology/CALHN Animal Ethics Committee and the 
University of Adelaide Animal Ethics Committee. 
The NIH3T3 cell lines expressing varying levels 
of SK2 described above were trypsinized and washed 
in PBS, and 1x106 cells were injected in 200 µl of PBS 
subcutaneously into the flank of 8 week old female NOD/
SCID mice. The empty vector cells with ‘low’ GFP 
expression were selected as a representative control group. 
Mice were examined daily to monitor tumor formation. On 
day 19, all mice were humanely killed and tumors were 
excised. Half of each tumor was fixed in 10% formalin, 
paraffin embedded and sectioned. The remaining half 
was homogenized using a pestle (Axygen) in extraction 
buffer, subjected to freeze/thawing in liquid nitrogen and 
sonication, and lysates were clarified by centrifugation at 
17,000 × g for 15 min at 4°C. 
Sphingosine kinase activity assays
SK1 and SK2 activity was determined as previously 
described, using isoform-selective assay conditions [46].
Immunohistological analyses
Immunohistological staining was performed 
as previously described [36], with the following 
modifications. For PECAM-1 (CD31) expression, 
sections were blocked with rabbit serum, incubated 
with goat polyclonal antibody to PECAM-1 (Santa 
Cruz Biotechnology) at 133 ng/ml, and biotinylated 
rabbit anti-goat secondary antibody (1:500; Abcam). For 
FLAG-tagged SK2 expression, sections were blocked 
with goat serum, incubated with rabbit polyclonal FLAG 
antibody (Cell Signaling Technology) at 150 ng/ml, and 
biotinylated goat anti-rabbit secondary antibody (1:500; 
Vector Labs). Sections were visualized on an EVOS XL 
light microscope (Life Technologies) at 20x magnification.
Immunofluorescence analyses
For dual immunofluorescence staining of 
overexpressed FLAG-tagged SK2 and Ki-67 on the 
formalin-fixed paraffin-embedded tumor tissue samples, 
sections were de-waxed, rehydrated, and antigen retrieval 
was performed by boiling in citrate buffer for 30 min. 
Sections were blocked in 10% goat serum diluted in CAS-
Block (Thermo Fisher Scientific) for 30 min. Following 
blocking, sections were incubated overnight at 4°C with 
mouse monoclonal anti-Ki-67 antibody (1:20; Vector 
Labs) and rabbit polyclonal anti-FLAG antibody (1:100; 
Cell Signaling Technology) diluted together in 10% goat 
serum/CAS-Block. Sections were then incubated for 1 
h at room temperature with goat anti-mouse AlexaFluor 
488 (1:400) and goat anti-rabbit AlexaFluor 594 (1:400) 
secondary antibodies (Thermo Fisher Scientific) diluted 
together in 10% goat serum/CAS-Block. Labelled sections 
were then mounted in Vectashield mounting medium 
containing DAPI (Vector Labs) and were imaged using 
a Zeiss LSM 700 confocal microscope (Jena, Germany). 
To examine the subcellular localization of 
overexpressed FLAG-tagged SK2, NIH3T3 SK2 ‘low’ 
and ‘high’ stable cell lines were seeded onto 8-well glass 
chamber slides (Nalge Nunc International) coated with 
poly-L-lysine (Sigma-Aldrich) at 4x104 cells/well, and 
grown overnight in DMEM with 10% DBS. Media was 
then removed and replaced with DMEM containing 0.5% 
DBS, and cells were cultured for a further 16 h. Cells 
were then fixed in 4% paraformaldehyde for 10 min, 
permeabilized for 10 min in PBS with 0.1% Triton X-100, 
and blocked in 5% goat serum in PBS with 0.1% Triton 
X-100 for 60 min. Rabbit monoclonal anti-FLAG antibody 
(1:200; Cell Signaling Technology) and mouse anti-γ-
catenin antibody (1:500; BD Biosciences) were incubated 
for 1.5 h at room temperature, followed by goat anti-rabbit 
AlexaFluor 594 and goat anti-mouse AlexaFluor 488 
secondary antibodies (1:500; Thermo Fisher Scientific) 
for 1 h. Cells were counterstained with DAPI to identify 
nuclei (blue). Fluorescence microscopy and imaging were 
performed using a Zeiss LSM 700 confocal microscope. 
Measuring rate of extracellular S1P production
Rate of extracellular S1P formation from intact 
vector control ‘low’, SK2 ‘low’ and SK2 ‘high’ NIH3T3 
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stable cell lines was determined essentially as previously 
described [47]. Briefly, cells were seeded in equal 
numbers at 80% confluence (in 20 cm2 dishes), and media 
was replaced with DMEM containing 0.5% DBS and 
incubated for a further 16 h. Cells were then labelled with 
0.5 µCi of [3H]-sphingosine (Perkin-Elmer, Rowville, 
VIC, Australia) for 30 min, after which the conditioned 
media was collected. Extracellular [3H]-S1P generated in 
the conditioned medium was extracted and analyzed by 
scintillation counting.
Intracellular sphingolipid analyses
Vector control ‘low’, SK2 ‘low’ and SK2 ‘high’ 
NIH3T3 stable cell lines were grown in DMEM with 
10% DBS to 80% confluence, media was replaced with 
DMEM containing 0.5% DBS and cells were cultured 
for 16 h. Cells were trypsinized, quenched and washed in 
PBS. Cells were pelleted in quadruplicate with 8.8x106 
cells per sample, and intracellular sphingolipid species 
were analyzed by LC-MS, as previously described [48] 
with the following minor modifications. Prepared samples 
were injected onto an Ascentis Express C18 column 
(Supelco Analytical, Bellefonte, PA, USA), and non-
natural sphingolipid internal standards were added to each 
sample to allow relative quantification. Data analysis was 
performed using Tracefinder (Thermo Fisher Scientific).
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